Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OrthoLogic, dj Orthopedics Seek Alternative Paths To Healing Bones

This article was originally published in The Gray Sheet

Executive Summary

OrthoLogic will focus on commercializing its Chrysalin synthetic peptide technology for tissue and bone repair with proceeds from the sale of its electromagnetic bone stimulation business

You may also be interested in...



People In Brief

FDA Deputy Commissioner for Policy: Amit Sachdev leaves the agency to pursue private-sector opportunities after serving more than eight years in various government positions and roughly a year at one of the three deputy-commissioner posts created by Acting Commissioner Lester Crawford in the top-level restructuring that followed Mark McClellan's 2004 departure. As FDA's legislative liaison, Sachdev was involved with MDUFMA (1"The Gray Sheet" Sept. 23, 2002, p. 4). Crawford's confirmation as FDA's permanent chief could create another opportunity to revisit its leadership structure...

People In Brief

FDA Deputy Commissioner for Policy: Amit Sachdev leaves the agency to pursue private-sector opportunities after serving more than eight years in various government positions and roughly a year at one of the three deputy-commissioner posts created by Acting Commissioner Lester Crawford in the top-level restructuring that followed Mark McClellan's 2004 departure. As FDA's legislative liaison, Sachdev was involved with MDUFMA (1"The Gray Sheet" Sept. 23, 2002, p. 4). Crawford's confirmation as FDA's permanent chief could create another opportunity to revisit its leadership structure...

OrthoLogic partnership opportunities

Firm's Chrysalis BioTechnology acquisition for $27.5 mil. in cash and stock (plus up to $7 mil. in milestones) stems from an earlier licensing pact for development-phase, Chrysalin synthetic peptide-based therapeutics for orthopedic indications. The purchase provides rights beyond orthopedics: OrthoLogic is considering partnering with a device firm to market a Chrysalin-based cardiovascular drug that could be delivered via catheter for ischemia, CEO Thomas Trotter said April 29. The firm also is pondering partnerships to speed development of five Chrysalin-based products for orthopedic indications (1"The Gray Sheet" Oct. 13, 2003, p. 12)...

Related Content

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel